Diabetes Metab J.
2013 Feb;37(1):83-84. 10.4093/dmj.2013.37.1.83.
Response: The Risk of Bladder Cancer in Korean Diabetic Subjects Treated with Pioglitazone (Diabetes Metab J 2012;36:371-8)
- Affiliations
-
- 1Division of Endocrinology and Metabolism, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. bwanlee@yuhs.ac
- KMID: 2280747
- DOI: http://doi.org/10.4093/dmj.2013.37.1.83
Abstract
- No abstract available.
Reference
-
1. Kahn SE, Zinman B, Lachin JM, Haffner SM, Herman WH, Holman RR, Kravitz BG, Yu D, Heise MA, Aftring RP, Viberti G. Diabetes Outcome Progression Trial (ADOPT) Study Group. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care. 2008. 31:845–851.2. Dowdy D. Tobacco smoking and bladder cancer. JAMA. 2011. 306:2216–2217.3. World Health Organization. WHO report on the global tobacco epidemic, 2011: warning about the dangers of tobacco. 2011. Geneva: World Health Organization.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Letter: The Risk of Bladder Cancer in Korean Diabetic Subjects Treated with Pioglitazone (Diabetes Metab J 2012;36:371-8)
- Response: The Risk of Bladder Cancer in Korean Diabetic Subjects Treated with Pioglitazone (Diabetes Metab J 2012;36:371-8)
- Letter: The Risk of Bladder Cancer in Korean Diabetic Subjects Treated with Pioglitazone (Diabetes Metab J 2012;36:371-8)
- The Risk of Bladder Cancer in Korean Diabetic Subjects Treated with Pioglitazone
- Response: Impact of HbA1c Criterion on the Detection of Subjects with Increased Risk for Diabetes among Health Check-Up Recipients in Korea (Diabetes Metab J 2012;36:151-6)
